SV7 Impact Medicine Fund LP 4/A

Accession 0000899243-21-042710

CIK 0001840233other

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 4:20 PM ET

Size

24.9 KB

Accession

0000899243-21-042710

Form 4/AAmended

Period: 2021-10-26

10% Owner

Transactions

Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total
→ Common Stock (998,544 underlying)
Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total
→ Common Stock (302,588 underlying)
Conversion
Common Stock
2021-10-26+998,544→ 998,544 total
Purchase
Common Stock
2021-10-26$16.00/sh+312,500$5,000,000→ 1,613,632 total(indirect: See footnote)
Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total(indirect: See footnote)
→ Common Stock (998,544 underlying)
Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total
Purchase
Common Stock
2021-10-26$16.00/sh+312,500$5,000,000→ 1,613,632 total
Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total(indirect: See footnote)
→ Common Stock (302,588 underlying)
Conversion
Common Stock
2021-10-26+998,544→ 998,544 total(indirect: See footnote)
Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total(indirect: See footnote)

10% Owner

Transactions

Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total
Purchase
Common Stock
2021-10-26$16.00/sh+312,500$5,000,000→ 1,613,632 total(indirect: See footnote)
Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total(indirect: See footnote)
→ Common Stock (998,544 underlying)
Conversion
Common Stock
2021-10-26+998,544→ 998,544 total(indirect: See footnote)
Purchase
Common Stock
2021-10-26$16.00/sh+312,500$5,000,000→ 1,613,632 total
Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total
→ Common Stock (302,588 underlying)
Conversion
Common Stock
2021-10-26+998,544→ 998,544 total
Conversion
Series B Convertible Preferred Stock
2021-10-26−9,486,166→ 0 total
→ Common Stock (998,544 underlying)
Conversion
Series C Convertible Preferred Stock
2021-10-26−2,874,595→ 0 total(indirect: See footnote)
→ Common Stock (302,588 underlying)
Conversion
Common Stock
2021-10-26+302,588→ 1,301,132 total(indirect: See footnote)

Footnotes (4)

[F1]The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date.
[F2]Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021.
[F3]Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom.
[F4]This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering.

Documents

1 file

Xilio Therapeutics, Inc.

CIK 0001840233

Entity typeother

IncorporatedUnited Kingdom